With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

My Green Lab's 2024 report reveals growing climate commitments from the biotech and pharma sectors while underscoring the urgency of accelerating Scope 3 emissions reductions. BAKU, AZERBAIJAN ...

An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On July 9, 2025, Moleculin Biotech announced that the Regulation Agency for ...

In this week's edition of "Adam's Biotech Scorecard," Adam also explains why he's not worried — yet — about drugmakers reporting FDA delays.

The last biotech IPO of note was the $98 million debut of obesity-drug focused Aardvark Therapeutics Inc. in mid-February.

In biotech, capital is a lifeline. Scientific progress alone doesn’t bring therapies to patients; sustained funding helps. With long development timelines and high burn rates, biotech companies ...